Compare Inovio Pharmaceuticals Inc (INO) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Southern Copper Corp trades at $194.3 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 2090.5× Inovio Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SCCO | |
|---|---|---|
Market Cap | $78.55M | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $218.85 |
52-Week Low | $0.66 | $93.70 |
Enterprise Value | $49.56M | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Southern Copper (SCCO) trades at $193.14, down 3.48% on the day, amid a broader copper price pullback. The stock exhibits strong fundamentals with revenue growth from $13.42B in 2025 to a projected $15.8B in 2026 and robust profitability margins, including a net income margin of 35.87%. Recent quarters have consistently beaten EPS estimates, and technical indicators show a bullish trend with key support at $191. However, the stock trades at a premium valuation with a P/E of 29.18, above the analyst consensus price target of $153.64.
The outlook for SCCO is mixed; strong earnings growth and exposure to copper demand from AI and data centers present upside, but high valuation and reliance on volatile metal prices pose risks. Analyst sentiment is cautious with only 10.34% buy ratings, suggesting limited near-term upside from current levels despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
